Tolerance to a new free amino acid-based formula in children with IgE or non-IgE-mediated cow’s milk allergy: a randomized controlled clinical trial

BMC Pediatrics

Riccardo Troncone³  Linda Cosenza²  Annalisa Passariello¹  Gianluca Terrin³  Margherita Di Costanzo²  Ludovica Leone²  Rita Nocerino²  Roberto Berni Canani³ 

[1] Monaldi Hospital, Naples, Italy;Department of Paediatrics, European Laboratory for the Investigation of Food Induced Diseases (ELFID), University of Naples “Federico II”, Via S. Pansini, 5-80131, Naples, Italy;Department of Women’s Health and Territorial Medicine, University “La Sapienza”, Rome, Italy

关键词: Dietotherapy;    Infant formula;    Eosinophilic cationic protein;    Faecal calprotectin;    Food allergy;   

Others  :  1164254
DOI  :  10.1186/1471-2431-13-24

 received in 2012-05-31, accepted in 2013-01-31,  发布年份 2013

【 摘 要 】

Background

Amino acid-based formulas (Aaf) are increasingly used in children with cow’s milk allergy (CMA). To be labeled hypoallergenic these formulas must demonstrate in clinical studies that they don’t provoke reactions in 90% of subjects with confirmed CMA with 95% confidence when given in prospective randomized, double-blind, placebo-controlled challenge (DBPCFC) trials. The majority of available safety data on Aaf derived from patients with IgE-mediated CMA. Considering substantial differences in the immunologic mechanism and clinical presentation of non-IgE-mediated CMA it’s important to investigate the hypoallergenicity of these formulas also in these patients. We prospectively assessed the tolerance to a new commercially available Aaf in children affected by IgE- or non-IgE-mediated CMA.

Methods

Consecutive patients affected by IgE- or non-IgE-mediated CMA, aged ≤ 4 years, were enrolled. DBPCFC was carried out with increasing doses of the new Aaf (Sineall, Humana, Milan, Italy), using validated Aaf as placebo. Faecal concentrations of calprotectin (FC) and eosinophilic cationic protein (ECP) were monitored.

Results

Sixty patients (44 male, 73.3%, median age 37, 95%CI 34.5–39.6 months, IgE-mediated CMA 29, 48.3%) were enrolled. At the diagnosis clinical symptoms were gastrointestinal (46.6%), cutaneous (36.6%), respiratory (23.3%), and systemic (10.0%). After DBPCFC with the new Aaf, no patient presented early or delayed clinical reactions. Faecal concentration of calprotectin and of ECP remained stable after the exposure to the new Aaf.

Conclusions

The new Aaf is well tolerated in children with IgE- or non-IgE-mediated CMA, and it could be used as a safe dietotherapy regimen for children with this condition.

Trial registration

The trial was registered in the ClinicalTrials.gov Protocol Registration System (ID number: NCT01622426).

【 授权许可】

   
2013 Berni Canani et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Rona RJ, Keil T, Summers C, Gislason D, Zuidmeer L, Sodergren E, et al.: The prevalence of food allergy: a meta-analysis. J Allergy Clin Immunol 2007, 120:638-646.
• [2]Fiocchi A, Brozek J, Schünemann H, Bahna SL, von Berg A, Beyer K, et al.: World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow’s Milk Allergy (DRACMA) Guidelines. Pediatr Allergy Immunol 2010, 21(Suppl 21):1-125.
• [3]American Academy of Pediatrics Committee on Nutrition: Hypoallergenic infant formulae. Pediatrics 2000, 106:346-349.
• [4]Eastham EJ, Lichauco T, Pang K, Walker WA: Antigenicity of infant formulas and the induction of systemic immunologic tolerance by oral feeding: cow’s milk versus soy milk. J Pediatr Gastroenterol Nutr 1982, 1:23-28.
• [5]American Academy of Pediatrics: Committee on Nutrition. Soy protein-based formulas: recommendations for use in infant feeding. Pediatrics 1998, 101:53-148.
• [6]Businco L, Bruno G, Giampietro PG, Cantani A: Allergenicity and nutritional adequacy of soy protein formulas. J Pediatr 1992, 121:S21-S28.
• [7]Klemola T, Vanto T, Juntunen-Backman K, Kalimo K, Korpela R, Varjonen E: Allergy to soy formula and to extensively hydrolysed whey formula in infants with cow’s milk allergy: a prospective, randomized study with a follow-up to the age of 2 years. J Pediatr 2002, 140:219-224.
• [8]Zeiger RS, Sampson HA, Bock SA, et al.: Soy allergy in infants and children with IgE-associated cow’s milk allergy. J Pediatr 1999, 134:614-622.
• [9]McLeish CM, MacDonald A, Booth IW: Comparison of an elemental with a hydrolysed whey formula in intolerance to cow’s milk. Arch Dis Child 1995, 73:211-215.
• [10]Sicherer SH, Noone SA, Koerner CB, Christie L, Burks AW, Sampson HA: Hypoallergenicity and efficacy of an amino acid based formula in children with cow’s milk and multiple food hypersensitivities. J Pediatr 2001, 138:688-693.
• [11]Hill DJ, Murch SH, Rafferty K, Wallis P, Green CJ: The efficacy of amino acid-based formulas in relieving the symptoms of cow’s milk allergy: a systematic review. Clin Exp Allergy 2007, 37:808-822.
• [12]de Boissieu D, Dupont C: Allergy to extensively hydrolyzed cow’s milk proteins in infants: safety and duration of amino acid– based formula. J Pediatr 2002, 141:271-273.
• [13]de Boissieu D, Matarazzo P, Dupont C: Allergy to extensively hydrolyzed cow’s milk proteins in infants: identification and treatment with an amino acid–based formula. J Pediatr 1997, 131:744-747.
• [14]Niggemann B, Binder C, Dupont C, Hadji S, Arvola T, Isolauri E: Prospective, controlled, multi-center study on the effect of an amino acid– based formula in infants with cow’s milk allergy/intolerance and atopic dermatitis. Pediatr Allergy Immunol 2001, 12:78-82.
• [15]Bindslev-Jensen C, Ballmer-Weber BK, Bengtsson U, et al.: Standardization of food challenges in patients with immediate reactions to foods-position paper from the European Academy of Allergology and Clinical Immunology. Allergy 2004, 59:690-697.
• [16]Berni Canani R, Rapacciuolo L, Romano MT, Tanturri de Horatio L, Terrin G, Manguso F, et al.: Diagnostic value of faecal calprotectin in pediatric gastroenterology clinical practice. Dig Liver Dis 2004, 36:467-470.
• [17]Baldassarre ME, Laforgia N, Fanelli M, Laneve A, Grosso R, Lifschitz C: Lactobacillus GG improves recovery in infants with blood in the stools and presumptive allergic colitis compared with extensively hydrolyzed formula alone. J Pediatr 2010, 156:397-401.
• [18]Carroccio A, Brusca I, Mansueto P, Soresi M, D’Alcamo A, Ambrosiano G, Pepe I, Iacono G, Lospalluti ML, La Chiusa SM, Di Fede G: Fecal assays detect hypersensitivity to cow’s milk protein and gluten in adults with irritable bowel syndrome. Clin Gastroenterol Hepatol 2011, 9:965-971.
• [19]Majamaa H, Laine S, Miettinen A: Eosinophil protein X and eosinophil cationic protein as indicators of intestinal inflammation in infants with atopic eczema and food allergy. Clin Exp Allergy 1999, 29:1502-1506.
• [20]Sampson HA, Bernhisel-Broadbent J, Yang E, et al.: Safety of casein hydrolysate formula in children with cow milk allergy. J Pediatr 1991, 118:520-525.
• [21]Host A, Koletzko B, Dreborg S, et al.: Dietary products used in infants for treatment and prevention of food allergy. Joint Statement of the European Society for Paediatric Allergology and Clinical Immunology (ESPACI) Committee on Hypoallergenic Formulas and the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Committee on Nutrition. Arch Dis Child 1999, 81:80-84.
• [22]Berni Canani R, Ruotolo S, Auricchio L, Caldore M, Porcaro F, Manguso F, Terrin G, Troncone R: Diagnostic accuracy of the atopy patch test in children with food allergy-related gastrointestinal symptoms. Allergy 2007, 62:738-743.
• [23]Berni Canani R, Buongiovanni A, Nocerino R, Cosenza L, Troncone R: Toward a standardized reading of the atopy patch test in children with suspected cow’s milk allergy-related gastrointestinal symptoms. Allergy 2011, 66:1499-1500.
• [24]Berni Canani R, Nocerino R, Terrin G, Coruzzo A, Cosenza L, Leone L, Troncone R: Effect of Lactobacillus GG on tolerance acquisition in infants with cow’s milk allergy: a randomized trial. J Allergy Clin Immunol 2012, 129:580-582.
• [25]Berni Canani R, Tanturri de Horatio L, Terrin G, Romano MT, Miele E, Staiano A, et al.: The combined use of non-invasive tests is useful in the initial diagnostic approach to a child with suspected inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2006, 42:9-15.
• [26]Berni Canani R, Ruotolo S, Discepolo V, Troncone R: The diagnosis of food allergy in children. Curr Opin Pediatr 2008, 20:584-589.
• [27]Schlimme E, Martin D, Meisel H: Nucleosides and nucleotides: natural bioactive substances in milk and colostrum. Br J Nutr 2000, 84(Suppl 1):S59-S68.
• [28]Cosgrove M: Perinatal and infant nutrition. Nucleotides Nutrition 1998, 14:748-751.
• [29]Hess JR, Greenberg NA: The role of nucleotides in the immune and gastrointestinal systems: potential clinical applications. Nutr Clin Pract 2012, 27:281-294.